|
28 Nov 2019 |
Social |
RT @RheumNow: Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activ… |
|
|
26 Nov 2019 |
Social |
The EMA has approved a subcutaneous version of Celltrion infliximab biosimilar, CT-P13 - now called Remsima SC; based on the phase I/III study showing equivalence between SC and IV forms of CT-P13 SC in active rheumatoid arthritis (RA). https://t.co/cJFEk464Wr |
|
|
26 Nov 2019 |
News |
BMS and Celgene Merge as Amgen Buys Otezla |
|
|
21 Nov 2019 |
Social |
FINCH3: FILGOTINIB studied in this cohort naive to MTX; interesting that safety data looks good! Maybe too early to tell. Abst# 927 https://t.co/AonswiGYG3 https://t.co/q3OU582WbT |
|
|
20 Nov 2019 |
News |
ACR 2019 – Best of the Plenary Sessions |
|
|
20 Nov 2019 |
ACR Video |
Subcutaneous Biosimilar: Dr. Jonathan Kay |
|
|
18 Nov 2019 |
ACR Video |
Emapalumab Treatment in Macrophage Activation Syndrome: Dr. Fabrizio De Benedetti |
|
|
18 Nov 2019 |
ACR Video |
Biosimilars: Dr. Arthur Kavanaugh |
|
|
18 Nov 2019 |
Social |
The FDA has approved Pfizers new adadliumab biosimilar - Abrilada (adalimumab-afzb), this is the 5th adalimumab biosimilar to be approved (none are commercially available in the USA until 2023). Abrilada is the 25th biosimilar approved in the U.S. https://t.co/Z0tp3D5yOd |
|
|
13 Nov 2019 |
Social |
RT @CCalabreseDO: Continue or stop biologics for RA if pregnant? Abstr# 2292 and 2279 show increase in flares, GC use, if biologics stopped… |
|
|
13 Nov 2019 |
Social |
RT @Janetbirdope: Tofa is not different from bDMARDs in Corrona for cancer and deaths. reassuring and adds to growing safety data #ACR #ACR… |
|
|
13 Nov 2019 |
Social |
RT @EBRheum: Great talk by Dr. Manzi for Year in Review!
See my recent podcast about SPIRIT-H2H. It shows that IXE > ADA for skin but NO… |
|
|
12 Nov 2019 |
Social |
RT @DrKanikaMonga: Efficacy and Safety of Upadacitinib in a
Randomized, Double-Blind, Placebo-Controlled,
Multicenter Phase 2/3 Clinical St… |
|
|
12 Nov 2019 |
Social |
RT @hausmannMD: Secukinumab: a human IgG1κ monoclonal antibody that binds to IL-17A
ASAS40: a composite measure including patient global,… |
|
|
12 Nov 2019 |
Social |
RT @DrPetryna: Do you routinely consider ACPA status in your choice of Biologic MOA? |
|
|
12 Nov 2019 |
Social |
RT @hausmannMD: Telitacicept is a recombinant fusion protein with the extracellular domain of TACI and the FC domain of human IgG1. #ACR19… |
|
|
12 Nov 2019 |
Social |
RT @uptoTate: Drs. Davila and Solow say “No good data to suggest that biologic DMARDs contribute to progression of MGUS so okay to treat as… |
|
|
12 Nov 2019 |
Social |
RT @uptoTate: Spending and price trending of bDMARDs. https://t.co/gB6xjvialr #ACR19 @RheumNow plenary#2731 https://t.co/YNpwYvTu1y |
|
|
12 Nov 2019 |
Social |
RT @philipcrobinson: Yes, you read that right US$5,000,000,000 increase in biological DMARD spending #ACR19 @RheumNow Abs 2731 https://t.co… |
|
|
12 Nov 2019 |
Social |
RT @EBRheum: @RheumNow Should note this was not the first JAKi in this space; similar trial using tofacitinib in 2017 https://t.co/NrEul0wL… |
|
